Ice cream fans that are hoping to get their hands on a free Dairy Queen Blizzard are in luck.
Source: Shutterstock
A new offer from the restaurant chain will allow customers to pick up one free Dairy Queen Blizzard. However, there are a few things they need to know about the offer before running off to their local store.
The offer is only available for one free Dairy Queen Blizzard of the treat size. Also, customers can’t just walk in and expect a free DQ Blizzard. Instead, they will have to download the company’s mobile app and register for an account.
Top 5 High Tech Stocks To Own Right Now: W&T Offshore Inc.(WTI)
Advisors' Opinion:- [By Joseph Griffin]
W&T Offshore, Inc. (NYSE:WTI) – Equities research analysts at Seaport Global Securities lifted their Q3 2018 EPS estimates for shares of W&T Offshore in a research report issued to clients and investors on Wednesday, September 26th. Seaport Global Securities analyst J. Aschenbeck now forecasts that the oil and gas company will post earnings per share of $0.16 for the quarter, up from their prior estimate of $0.14. Seaport Global Securities has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for W&T Offshore’s Q1 2019 earnings at $0.21 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.18 EPS, Q4 2019 earnings at $0.19 EPS and FY2019 earnings at $0.76 EPS.
- [By Dan Caplinger]
The stock market had a mixed day on Wednesday, with gains for the Dow Jones Industrial Average coming largely at the expense of the tech-heavy Nasdaq Composite, as well as smaller-company stocks. Investors were encouraged by solid economic data showing strength in the housing market, and strength in the financial sector was especially helpful for the Dow. Nervousness about potential regulation of high-flying tech stocks dampened market sentiment to some extent, but a few individual stocks posted sizable gains. GW Pharmaceuticals (NASDAQ:GWPH), Baidu (NASDAQ:BIDU), and W&T Offshore (NYSE:WTI) were among the best performers on the day. Here's why they did so well.
- [By Shane Hupp]
Weatherly International plc (LON:WTI) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.09 ($0.00) and last traded at GBX 0.19 ($0.00), with a volume of 58655113 shares. The stock had previously closed at GBX 0.19 ($0.00).
Top 5 High Tech Stocks To Own Right Now: Advent Claymore Convertible Securities and Income Fund(AVK)
Advisors' Opinion:- [By Max Byerly]
Saba Capital Management L.P. lessened its stake in Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) by 91.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,101 shares of the investment management company’s stock after selling 255,542 shares during the period. Saba Capital Management L.P. owned 0.11% of Advent Claymore Convertible Sec & Inc Fd worth $384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
- [By Ethan Ryder]
Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) insider Tracy V. Maitland purchased 50,000 shares of Advent Claymore Convertible Sec & Inc Fd stock in a transaction dated Thursday, September 6th. The shares were acquired at an average cost of $15.68 per share, for a total transaction of $784,000.00. Following the completion of the transaction, the insider now owns 12,000 shares of the company’s stock, valued at approximately $188,160. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
- [By Ethan Ryder]
Advent Claymore Convertible Sec & Inc Fd (NYSE:AVK) VP Tony Huang bought 2,066 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was acquired at an average cost of $15.66 per share, for a total transaction of $32,353.56. Following the completion of the acquisition, the vice president now directly owns 7,100 shares in the company, valued at $111,186. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Top 5 High Tech Stocks To Own Right Now: Heron Therapeutics, Inc. (HRTX)
Advisors' Opinion:- [By Max Byerly]
Heron Therapeutics Inc (NASDAQ:HRTX) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Thursday, July 19th. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will post earnings of ($0.23) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock.
- [By Max Byerly]
Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Dan Caplinger]
Thursday was a poor day on Wall Street, with major benchmarks giving up about 0.5%-1% across the board. Trade concerns remain the focal point for market participants, with the latest controversy over U.S. immigration policy posing a potential threat to relations with traditional American allies abroad as well. Even with worries on a big-picture level, some individual companies had good news that sent their shares higher. Stitch Fix (NASDAQ:SFIX), Barnes & Noble Education (NYSE:BNED), and Heron Therapeutics (NASDAQ:HRTX) were among the best performers on the day. Here's why they did so well.
- [By George Budwell]
Shares of the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) gained as much as 36.3% today on abnormally high volume. What triggered this massive surge higher?
- [By George Budwell]
As things stand now, Cara's immediate future hinges directly on the strength of Korsuva's late-stage results in both postoperative pain and CKD-associated pruritus. Having said that, I think investors should largely consider the drug's postoperative pain indication as icing on the cake at this point. Heron Therapeutics' (NASDAQ:HRTX)experimental pain medicine HTX-011, after all, appears to have a sizable advantage in terms of efficacy over Korsuva based on the trial data so far. And Heron is almost certainly going to beat Cara to market by several years as well, giving it a formidable first-mover advantage.
Top 5 High Tech Stocks To Own Right Now: Intuitive Surgical Inc.(ISRG)
Advisors' Opinion:- [By Brian Feroldi]
TransEnterix (NYSEMKT:TRXC) recently surprised investors on the upside when it reported its first-quarter results. The company's Senhance surgical system is off to a fast start right out of the gate, and it has attracted a lot of positive attention from the medical community. This just goes to show how much demand is out there for an alternative to Intuitive Surgical's (NASDAQ: ISRG) dominant da Vinci platform.
- [By Anders Bylund]
Shares of Intuitive Surgical (NASDAQ:ISRG) rose 10.2% in August 2018, according to data from S&P Global Market Intelligence. The maker of the da Vinci robotic surgery platform and its associated tools didn't need any actual news to keep its impressive market momentum going.
- [By Motley Fool Staff]
In this segment from MarketFoolery, host Chris Hill and Motley Fool Asset Management's Bill Barker consider the case for healthcare innovator Intuitive Surgical (NASDAQ:ISRG), which has been on a tear for the past few years. Its pricey robots are growing ever more common and popular with hospitals and doctors, and based on the reaction of the market, investors must expect its current sales growth pace to continue.
- [By Daniel Sparks]
As earnings season begins to kick into gear, next week features stocks of all shapes and sizes. But two stocks I'll be watching are growth stocks Netflix (NASDAQ:NFLX) and Intuitive Surgical (NASDAQ:ISRG). Both companies are benefiting from double-digit growth in revenue and earnings per share. When these companies report their second-quarter results next week, investors will be watching to see if they can keep executing well on the growth opportunities before them.
Top 5 High Tech Stocks To Own Right Now: Adaptimmune Therapeutics plc(ADAP)
Advisors' Opinion:- [By ]
Adaptimmune Therapeutics (ADAP) : "If you've speculated on this one, you've won. Let's move on."
Icahn Enterprises (IEP) : "I don't really know what they own so I can't recommend it."
- [By Ethan Ryder]
Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.
- [By Logan Wallace]
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
